The approval of Phesgo was based on noninferiority data demonstrating comparable efficacy and safety to intravenous pertuzumab and trastuzumab. The Food and Drug Administration (FDA) has approved ...
WASHINGTON, D.C., USA — The U.S. Food and Drug Administration announced Monday it has approved a new breast cancer treatment that can be administered at home by a healthcare professional. Phesgo, a ...
There are 2 phases of dosing. Phesgo’s initial dose contains pertuzumab 1200 mg, trastuzumab 600 mg, and hyaluronidase 30,000 units over 8 minutes. A second dose contains pertuzumab 600 mg, ...
The new combination product of pertuzumab with trastuzumab together with hyaluronidase (Phesgo, Roche), which can be administered by subcutaneous injection, has been recommended for approval in the ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Phesgo™ ...
The FDA today approved Phesgo, the combination of pertuzumab, trastuzumab and hyaluronidase-zzxf, for the treatment of adults with HER2-positive breast cancer. Phesgo (Genentech) — indicated for ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Many anticancer drugs — including BTK ...
“You have breast cancer.” These four words echo in your head as your mind swirls with questions. You ask yourself… “what comes next?”... “What does this mean for my family?”... “How will I navigate ...
Subcutaneous administration is preferred by patients, physicians and healthcare providers, and is associated with a reduction in healthcare costs1,2,3 Treatment with Phesgo is over 90% faster, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback